This Article Full Text (PDF) All Versions of this Article: 0269215508099860v1 23/5/394    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Albavera-Hernández, C. Articles by Idrovo, A. J Search for Related Content PubMed PubMed Citation Articles by Albavera-Hernández, C. Articles by Idrovo, A. J Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Botox Cerebral Palsy Social Bookmarking                         What's this?

Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials

National Institute of Public Health, Mexican Social Security Institute

Jorge M Rodríguez

National Institute of Public Health

Alvaro J Idrovo

Center for Health Systems Research, National Institute of Public Health CP 62100, Cuernavaca, Morelos, Mexico, ajidrovo{at}insp.mx

Objective: To assess the safety of botulinum toxin type A for children with cerebral palsy using data from randomized clinical trials.

Data sources: A search was conducted of MEDLINE database for the period January 1990 to February 2008. A complementary search was carried out of references from previous reviews. From 122 articles, 20 randomized clinical trials were selected for the review.

Review methods: Two authors independently assessed eligibility of the studies and methodological quality of those according to CONSORT guidelines. For each adverse effect, relative risk was calculated, and when more than one study reported adverse effects, a meta-analysis was carried out. Sensitivity analyses with different continuity corrections factors were performed when zero cases were reported in a study arm.

Results: There were 882 participants in the 20 studies included in the meta-analysis. Six studies reported zero adverse effects. Thirty-five different adverse events were reported. Botulinum toxin type A use was related to respiratory tract infection, bronchitis, pharyngytis, asthma, muscle weakness, urinary incontinence, falls, seizures, fever and unspecified pain. Two deaths were reported in the study with higher person-time follow-up (relative risk (RR) 4.69, 95% confidence interval (CI) 0.23—95).

Conclusions: Botulinum toxin type A has a good safety profile during the first months of use. However the occurrence of adverse events is more frequent among children with cerebral palsy than individuals with other conditions. Severe adverse events are potentially related with the use of botulinum toxin type A, but data are sparse and additional study is required to clarify the causal relation.

This version was published on May 1, 2009

Clinical Rehabilitation, Vol. 23, No. 5, 394-407 (2009)
DOI: 10.1177/0269215508099860


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J Idrovo, C. Albavera-Hernandez, and J. M Rodriguez Letter to the editor Clinical Rehabilitation, September 1, 2009; 23(9): 862 - 863. [PDF]